Trial
NCT01343641
Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Virginia
Collaborators
National Institutes of Health (NIH); Merck Sharp & Dohme LLC
Condition
Chronic Kidney Disease
Intervention
MK-0677
Why stopped
Could not obtain drug supply from manufacturer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-14